Funding for this research was provided by:
Prinses Beatrix Spierfonds (WAR08-24, WAR13-07, WAR14-26)
stichting Spieren voor Spieren (na)
Received: 30 June 2018
Accepted: 29 August 2018
First Online: 12 September 2018
Ethics approval and consent to participate
: The study protocol was approved by the Medical Ethics Review Committee (MERC) of the University Medical Center Utrecht. All participants and parents of participants younger than 18 years gave written informed consent.
: Not applicable.
: MS, RIW, ML, HJW and CAW declare that they have no competing interests. BB serves on scientific advisory board for Roche Hoffman-La Roche Ltd., Zurich LHB serves on scientific advisory boards for the Prinses Beatrix Spierfonds, Thierry Latran Foundation, Biogen Idec and Cytokinetics; received an educational grant from Baxter International Inc.; serves on the editorial board of Amyotrophic Lateral Sclerosis and the Journal of Neurology, Neurosurgery and Psychiatry; and receives research support from the Prinses Beatrix Fonds, Netherlands ALS Foundation, The European Community’s Health Seventh Framework Programme (grant agreement n° 259,867), The Netherlands Organization for Health Research and Development (Vici Scheme, JPND (SOPHIA, STRENGTH)).WLP serves on scientific advisory boards of Biogen and Avexis and the LMI070 data monitoring committee of Novartis and receives research support from the Prinses Beatrix Spierfonds, Netherlands ALS Foundation and Stichting Spieren voor Spieren.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.